Cargando…
Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty “sham” trials?
SUMMARY: The 5-year period following 2009 saw a steep reduction in vertebral augmentation volume and was associated with elevated mortality risk in vertebral compression fracture (VCF) patients. The risk of mortality following a VCF diagnosis was 85.1% at 10 years and was found to be lower for ballo...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer London
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394540/ https://www.ncbi.nlm.nih.gov/pubmed/29063215 http://dx.doi.org/10.1007/s00198-017-4281-z |
_version_ | 1783398917960892416 |
---|---|
author | Ong, K. L. Beall, D. P. Frohbergh, M. Lau, E. Hirsch, J. A. |
author_facet | Ong, K. L. Beall, D. P. Frohbergh, M. Lau, E. Hirsch, J. A. |
author_sort | Ong, K. L. |
collection | PubMed |
description | SUMMARY: The 5-year period following 2009 saw a steep reduction in vertebral augmentation volume and was associated with elevated mortality risk in vertebral compression fracture (VCF) patients. The risk of mortality following a VCF diagnosis was 85.1% at 10 years and was found to be lower for balloon kyphoplasty (BKP) and vertebroplasty (VP) patients. INTRODUCTION: BKP and VP are associated with lower mortality risks than non-surgical management (NSM) of VCF. VP versus sham trials published in 2009 sparked controversy over its effectiveness, leading to diminished referral volumes. We hypothesized that lower BKP/VP utilization would lead to a greater mortality risk for VCF patients. METHODS: BKP/VP utilization was evaluated for VCF patients in the 100% US Medicare data set (2005–2014). Survival and morbidity were analyzed by the Kaplan-Meier method and compared between NSM, BKP, and VP using Cox regression with adjustment by propensity score and various factors. RESULTS: The cohort included 261,756 BKP (12.6%) and 117,232 VP (5.6%) patients, comprising 20% of the VCF patient population in 2005, peaking at 24% in 2007–2008, and declining to 14% in 2014. The propensity-adjusted mortality risk for VCF patients was 4% (95% CI, 3–4%; p < 0.001) greater in 2010–2014 versus 2005–2009. The 10-year risk of mortality for the overall cohort was 85.1%. BKP and VP cohorts had a 19% (95% CI, 19–19%; p < 0.001) and 7% (95% CI, 7–8%; p < 0.001) lower propensity-adjusted 10-year mortality risk than the NSM cohort, respectively. The BKP cohort had a 13% (95% CI, 12–13%; p < 0.001) lower propensity-adjusted 10-year mortality risk than the VP cohort. CONCLUSIONS: Changes in treatment patterns following the 2009 VP publications led to fewer augmentation procedures. In turn, the 5-year period following 2009 was associated with elevated mortality risk in VCF patients. This provides insight into the implications of treatment pattern changes and associated mortality risks. |
format | Online Article Text |
id | pubmed-6394540 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer London |
record_format | MEDLINE/PubMed |
spelling | pubmed-63945402019-03-15 Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty “sham” trials? Ong, K. L. Beall, D. P. Frohbergh, M. Lau, E. Hirsch, J. A. Osteoporos Int Original Article SUMMARY: The 5-year period following 2009 saw a steep reduction in vertebral augmentation volume and was associated with elevated mortality risk in vertebral compression fracture (VCF) patients. The risk of mortality following a VCF diagnosis was 85.1% at 10 years and was found to be lower for balloon kyphoplasty (BKP) and vertebroplasty (VP) patients. INTRODUCTION: BKP and VP are associated with lower mortality risks than non-surgical management (NSM) of VCF. VP versus sham trials published in 2009 sparked controversy over its effectiveness, leading to diminished referral volumes. We hypothesized that lower BKP/VP utilization would lead to a greater mortality risk for VCF patients. METHODS: BKP/VP utilization was evaluated for VCF patients in the 100% US Medicare data set (2005–2014). Survival and morbidity were analyzed by the Kaplan-Meier method and compared between NSM, BKP, and VP using Cox regression with adjustment by propensity score and various factors. RESULTS: The cohort included 261,756 BKP (12.6%) and 117,232 VP (5.6%) patients, comprising 20% of the VCF patient population in 2005, peaking at 24% in 2007–2008, and declining to 14% in 2014. The propensity-adjusted mortality risk for VCF patients was 4% (95% CI, 3–4%; p < 0.001) greater in 2010–2014 versus 2005–2009. The 10-year risk of mortality for the overall cohort was 85.1%. BKP and VP cohorts had a 19% (95% CI, 19–19%; p < 0.001) and 7% (95% CI, 7–8%; p < 0.001) lower propensity-adjusted 10-year mortality risk than the NSM cohort, respectively. The BKP cohort had a 13% (95% CI, 12–13%; p < 0.001) lower propensity-adjusted 10-year mortality risk than the VP cohort. CONCLUSIONS: Changes in treatment patterns following the 2009 VP publications led to fewer augmentation procedures. In turn, the 5-year period following 2009 was associated with elevated mortality risk in VCF patients. This provides insight into the implications of treatment pattern changes and associated mortality risks. Springer London 2017-10-24 2018 /pmc/articles/PMC6394540/ /pubmed/29063215 http://dx.doi.org/10.1007/s00198-017-4281-z Text en © The Author(s) 2017, corrected publication 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. |
spellingShingle | Original Article Ong, K. L. Beall, D. P. Frohbergh, M. Lau, E. Hirsch, J. A. Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty “sham” trials? |
title | Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty “sham” trials? |
title_full | Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty “sham” trials? |
title_fullStr | Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty “sham” trials? |
title_full_unstemmed | Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty “sham” trials? |
title_short | Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty “sham” trials? |
title_sort | were vcf patients at higher risk of mortality following the 2009 publication of the vertebroplasty “sham” trials? |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394540/ https://www.ncbi.nlm.nih.gov/pubmed/29063215 http://dx.doi.org/10.1007/s00198-017-4281-z |
work_keys_str_mv | AT ongkl werevcfpatientsathigherriskofmortalityfollowingthe2009publicationofthevertebroplastyshamtrials AT bealldp werevcfpatientsathigherriskofmortalityfollowingthe2009publicationofthevertebroplastyshamtrials AT frohberghm werevcfpatientsathigherriskofmortalityfollowingthe2009publicationofthevertebroplastyshamtrials AT laue werevcfpatientsathigherriskofmortalityfollowingthe2009publicationofthevertebroplastyshamtrials AT hirschja werevcfpatientsathigherriskofmortalityfollowingthe2009publicationofthevertebroplastyshamtrials |